Global Cancer Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts

Publisher Name :
Date: 01-Apr-2017
No. of pages: 700
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Cancer Diagnostics Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Cancer Diagnostics Partnering 2010-2017 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer diagnostics partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Cancer diagnostics partnering contract documents

Top cancer diagnostics deals by value

This report provides details of the latest Cancer Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Cancer Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Diagnostics partnering deals.

The report presents financial deal term values for Cancer Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Cancer Diagnostics partnering field; both the leading deal values and most active Cancer Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,200 online deal records of actual Cancer Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Cancer Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Cancer Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Cancer Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Cancer Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Cancer Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Cancer Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Cancer Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Cancer Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer Diagnostics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer Diagnostics technologies and products.

Key benefits

Global Cancer Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

In-depth understanding of Cancer Diagnostics deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of Cancer Diagnostics agreements with numerous real life case studies

Detailed access to actual Cancer Diagnostics contracts entered into by leading biopharma companies

Identify most active Cancer Diagnostics dealmakers since 2010

Insight into terms included in a Cancer Diagnostics partnering agreement, with real world examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Cancer Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Cancer Diagnostics trends and structure of deals entered into by leading companies worldwide.

Cancer Diagnostics Partnering Terms and Agreements includes:

Trends in Cancer Diagnostics dealmaking in the biopharma industry since 2010

Analysis of Cancer Diagnostics deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life Cancer Diagnostics deals

Access to Cancer Diagnostics contract documents

Leading Cancer Diagnostics deals by value since 2010

Most active Cancer Diagnostics dealmakers since 2010

In Global Cancer Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 1,200 Cancer Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Cancer Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts

Table of Contents
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Diagnostics dealmaking
2.1. Introduction
2.2. Cancer Diagnostics partnering over the years
2.3. Most active Cancer Diagnostics dealmakers
2.4. Cancer Diagnostics partnering by deal type
2.5. Cancer Diagnostics partnering by therapy area
2.6. Deal terms for Cancer Diagnostics partnering
2.6.1 Cancer Diagnostics partnering headline values
2.6.2 Cancer Diagnostics deal upfront payments7
2.6.3 Cancer Diagnostics deal milestone payments
2.6.4 Cancer Diagnostics royalty rates

Chapter 3 - Leading Cancer Diagnostics deals
3.1. Introduction
3.2. Top Cancer Diagnostics deals by value

Chapter 4 - Most active Cancer Diagnostics dealmakers
4.1. Introduction
4.2. Most active Cancer Diagnostics dealmakers
4.3. Most active Cancer Diagnostics partnering company profiles

Chapter 5 - Cancer Diagnostics contracts dealmaking directory
5.1. Introduction
5.2. Cancer Diagnostics contracts dealmaking directory

Chapter 6 - Cancer Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Cancer Diagnostics deals by company A-Z
Appendix 2 - Cancer Diagnostics deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Cancer Diagnostics deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 - Cancer Diagnostics deals by therapy area
Appendix 5 -Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Cancer Diagnostics partnering since 2010
Figure 2: Active Cancer Diagnostics dealmaking activity since 2010
Figure 3: Cancer Diagnostics partnering by deal type since 2010
Figure 4: Cancer Diagnostics partnering by disease type since 2010
Figure 5: Cancer Diagnostics deals with a headline value
Figure 6: Cancer Diagnostics deals with an upfront value
Figure 7: Cancer Diagnostics deals with a milestone value
Figure 8: Cancer Diagnostics deals with a royalty rate value
Figure 9: Top Cancer Diagnostics deals by value since 2010
Figure 10: Most active Cancer Diagnostics dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • North America PSA Test Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 17-May-2017        Price: US 4480 Onwards        Pages: 122
    Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3 gene.The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis. The results are usually reported as nanograms of PSA per milliliter (ng/mL) of blood.Scope of the Report:This report focuses on the PSA Test in North America market, especially in United States, Can......
  • United States Prostate Cancer Diagnostics Market by Manufacturers, States, Type and Application, Forecast to 2022
    Published: 16-May-2017        Price: US 4480 Onwards        Pages: 119
    The prostate is a walnut-sized gland located behind the base of a man's penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to dia......
  • Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Report 2017
    Published: 26-Apr-2017        Price: US 4000 Onwards        Pages: 107
    In this report, the Asia-Pacific Checkpoint Inhibitors for Treating Cancer market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Checkpoint Inhibitors for Treating Cancer for these regions, from 2012 to 2022 (forecast), including - C......
  • North America HPV Testing Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 26-Apr-2017        Price: US 4480 Onwards        Pages: 122
    The human papillomavirus (HPV) test detects the presence of human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The HPV testing is further classified into three sub-segments, namely, follow-up testing, co-testing, HPV primary testing.Scope of the Report:This report focuses on the HPV Testing in North America market, especially in United States, Canada and Mexico. This report categorizes the market bas......
  • Cancer Diagnostics Markets in China
    Published: 17-Apr-2017        Price: US 4000 Onwards        Pages: 213
    China's demand for Cancer Diagnostics has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, in......
  • Cancer Diagnostics Industry Forecasts - China Focus
    Published: 17-Apr-2017        Price: US 1800 Onwards        Pages: 103
    This study focuses on China's Cancer Diagnostics industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. ......
  • Cancer Diagnostics Companies in China
    Published: 17-Apr-2017        Price: US 1800 Onwards        Pages: 53
    This study focuses on China's Cancer Diagnostics industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions ......
  • Global PSA Test Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 13-Apr-2017        Price: US 3480 Onwards        Pages: 122
    Prostate-specific antigen (PSA), also known as gamma-seminoprotein or kallikrein-3 (KLK3), is a glycoprotein enzyme encoded in humans by the KLK3 gene. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis. The results are usually reported as nanograms of PSA per milliliter (ng/mL) of blood. Scope of the Report: This report focuses on the PSA Test in Global market, especially in Nor......
  • Global Prostate Cancer Diagnostics Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 12-Apr-2017        Price: US 3480 Onwards        Pages: 119
    The prostate is a walnut-sized gland located behind the base of a man's penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to dia......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs